Schroder Investment Management Group Sells 94,087 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Schroder Investment Management Group cut its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 15.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 499,765 shares of the medical instruments supplier’s stock after selling 94,087 shares during the period. Schroder Investment Management Group’s holdings in ICU Medical were worth $77,064,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Citigroup Inc. increased its position in shares of ICU Medical by 100.4% during the 3rd quarter. Citigroup Inc. now owns 28,965 shares of the medical instruments supplier’s stock valued at $5,278,000 after purchasing an additional 14,512 shares during the last quarter. Cerity Partners LLC lifted its holdings in ICU Medical by 33.2% during the 3rd quarter. Cerity Partners LLC now owns 9,846 shares of the medical instruments supplier’s stock valued at $1,794,000 after buying an additional 2,454 shares in the last quarter. FMR LLC boosted its holdings in shares of ICU Medical by 2,676.6% in the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of ICU Medical by 16.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,997 shares of the medical instruments supplier’s stock worth $1,275,000 after buying an additional 991 shares during the period. Finally, MetLife Investment Management LLC lifted its stake in ICU Medical by 129.1% in the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock worth $2,258,000 after acquiring an additional 6,981 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Trading Down 0.9 %

Shares of ICUI opened at $138.86 on Tuesday. The firm has a 50-day moving average price of $153.92 and a 200 day moving average price of $163.53. The firm has a market capitalization of $3.40 billion, a P/E ratio of -30.39 and a beta of 0.73. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $93.36 and a 12-month high of $196.26.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ICUI shares. Raymond James set a $97.00 price objective on ICU Medical in a research report on Wednesday, March 12th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Wednesday, December 11th. Finally, StockNews.com cut shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Thursday, March 27th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.